Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior

Provided By PR Newswire

Last update: Nov 14, 2022

MILWAUKEE, Nov. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating Opiant (NASDAQ: OPNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Indivior.